Pacritinib in CMML

Status Recruiting

Clinical Trial Summary

This is a phase 1/2 trial of pacritinib in combination with azacitidine in patients with Chronic Myelomonocytic Leukemia (CMML). Patients will be newly diagnosed or previously treated but could not have received a prior JAK inhibitor. Patients who have previously been treated with a hypomethylating agent (HMA) must have received ≤ 1 cycle. Pacritinib will be initially tested at a dose of 200mg twice daily (dose level 0) in combination with azacitidine 75mg/m2, which can be administered subcutaneously or intravenously, for 7 days in a 28-day cycle. If there are 2 DLTs in the first 6 patients, there will be a dose escalation to pacritinib 100mg twice daily (dose level -1) and an additional 6 patients will be enrolled. Based on the phase 1, 3+3 dose de-escalation design, 6-12 patients will be enrolled in the phase 1 portion. After the completion of phase 1 and identification of the recommended phase 2 dose (RP2D), the trial will then proceed to phase 2 which will employ a Simon two stage design. This portion will include the 6 patients enrolled during the phase 1 portion at the MTD. An interim analysis for futility will occur. If 3 or fewer patients have had a clinical benefit (CB) or better, as defined by 2015 MDS/MPN IWG criteria, the PI and DSMC will meet to discuss the totality of the evidence and determine if the trial shall proceed. In the second stage, an additional 12 patients will be enrolled.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Chronic Myelomonocytic Leukemia
Leukemia
Leukemia, Myelomonocytic, Acute
Leukemia, Myelomonocytic, Chronic
Leukemia, Myelomonocytic, Juvenile

Clinical Trial Details

NCT number	NCT06159491
Study type	Interventional
Source	Icahn School of Medicine at Mount Sinai
Contact	Tina Czaplinska
Phone	917-841-2454
Email	tina.czaplinska@mssm.edu
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	September 2024
Completion date	May 2027

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT04093570` - A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers	Phase 2
Active, not recruiting	`NCT03289910` - Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia	Phase 2
Completed	`NCT01427881` - Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies	Phase 2
Recruiting	`NCT01133886` - Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure	Phase 2
Completed	`NCT01169012` - PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias	Phase 1
Completed	`NCT01233921` - Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer	N/A
Terminated	`NCT00509249` - Aflibercept in Treating Patients With Myelodysplastic Syndromes	Phase 2
Completed	`NCT01093586` - Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Phase 2
Terminated	`NCT00387426` - Sunitinib in Treating Patients With Idiopathic Myelofibrosis	Phase 2
Completed	`NCT00096122` - Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia	Phase 1/Phase 2
Completed	`NCT00171912` - Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes	Phase 2
Completed	`NCT00078858` - Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant	Phase 1/Phase 2
Completed	`NCT00052520` - Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation	Phase 1/Phase 2
Recruiting	`NCT03683433` - Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation	Phase 2
Recruiting	`NCT04980404` - Inqovi Maintenance Therapy in Myeloid Neoplasms	Phase 1
Active, not recruiting	`NCT03588078` - Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine	Phase 1/Phase 2
Withdrawn	`NCT06085638` - Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia	Phase 1/Phase 2
Recruiting	`NCT03999723` - Combining Active and Passive DNA Hypomethylation	Phase 2
Terminated	`NCT00852709` - Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias	Phase 1
Terminated	`NCT00589316` - Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome	Phase 1